Sentara Health Plans Laboratory Testing Policies
Sentara Health Plans has partnered with Avalon Healthcare Solutions for Laboratory Benefits Management (LBM). The laboratory testing policies are accessible through the links below. These policies have been modified for Sentara Health Plan’s various products to align with government program policies, rules, and/or state and federal contracts, but note that in case of conflict, the government program policies, rules, and/or state and federal contracts will take precedence.
DISCLAIMER: Application of coverage criteria is dependent upon an individual’s benefit coverage at the time of the request. If there is a conflict between this Policy and any relevant, applicable government policy [e.g. Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare] for a particular member, then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit their search website https://www.cms.gov/medicare-coverage-database/search.aspx or the manual website.
- F2019: Flow Cytometry
- G2002: Cervical Cancer Screening
- G2005: Vitamin D Testing
- G2006: Diabetes Mellitus Testing
- G2007: Prostate Biopsy Specimen Analysis
- G2008: Prostate Specific Antigen (PSA) Testing
- G2011: Diagnostic Testing of Iron Homeostasis & Metabolism
- G2013: Testosterone
- G2014: Vitamin B12 and Methylmalonic Acid Testing
- G2022: Biomarker Testing for Autoimmune Rheumatic Disease
- G2031: Allergen Testing
- G2035: Prenatal Screening (Nongenetic)
- G2036: Hepatitis Testing
- G2042: Pediatric Preventive Screening
- G2043: Celiac Disease Testing
- G2044: Helicobacter Pylori Testing
- G2045: Thyroid Disease Testing
- G2048: Biochemical Markers of Alzheimer Disease and Dementia
- G2050: Cardiovascular Disease Risk Assessment
- G2051: Bone Turnover Markers Testing
- G2054: Liquid Biopsy
- G2055: Prenatal Testing for Fetal Aneuploidy
- G2056: Diagnosis of Idiopathic Environmental Intolerance
- G2059: Epithelial Cell Cytology in Breast Cancer Risk Assessment
- G2060: Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing
- G2061: Fecal Calprotectin Testing in Adults
- G2063: Testing for Diagnosis of Active or Latent Tuberculosis
- G2098: Immune Cell Function Assay
- G2099: Intracellular Micronutrient Analysis
- G2100: In Vitro Chemoresistance and Chemosensitivity Assays
- G2105: Immunopharmacologic Monitoring of Therapeutic Serum Antibodies
- G2107: Measurement of Thromboxane Metabolites for ASA Resistance
- G2110: Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease
- G2113: Oral Cancer Screening and Testing
- G2115: Metabolite Markers of Thiopurines Testing
- G2119: Diagnostic Testing of Influenza
- G2120: Salivary Hormone Testing
- G2121: Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease
- G2123: Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases
- G2124: Serum Tumor Markers for Malignancies
- G2125: Urinary Tumor Markers for Bladder Cancer
- G2138: Evaluation of Dry Eyes
- G2143: Lyme Disease Testing
- G2148: Genetic Testing for Hereditary Hearing Loss
- G2149: Pathogen Panel Testing
- G2150: Biomarkers for Myocardial Infarction and Chronic Heart Failure
- G2153: Pancreatic Enzyme Testing for Acute Pancreatitis
- G2154: Folate Testing
- G2155: General Inflammation Testing
- G2156: Urine Culture Testing for Bacteria
- G2157: Diagnostic Testing of Common Sexually Transmitted Infections
- G2158: Testing for Vector-Borne Infections
- G2159: Streptococcus Testing
- G2164: Parathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing
- G2173: Gamma-glutamyl Transferase
- G2174: Coronavirus Testing in the Outpatient Setting
- G2181: Colorectal Cancer Screening
- M2003: Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers
- M2004: Lynch Syndrome
- M2012: Genetic Testing for Hereditary Hemochromatosis
- M2017: Genetic Testing For Cystic Fibrosis
- M2020: Molecular Diagnostics for Breast Cancer Prognosis
- M2021: Pharmacogenetic Testing
- M2024: Genetic Testing for Polyposis Syndromes
- M2025: Genetic Testing For Inherited Cardiomyopathies and Channelopathies
- M2026: Testing for Colorectal Cancer Management
- M2028: Genetic Testing for FMR1 Mutations
- M2029: Molecular Testing for Cutaneous Melanoma
- M2030: Testing for Targeted Therapy of Non-Small-Cell Lung Cancer
- M2032: Whole Genome and Whole Exome Sequencing
- M2033: Chromosomal Microarray and Low-pass Whole Genome Sequencing
- M2038: Genetic Testing For Familial Alzheimer Disease
- M2039: Pre-Implantation Genetic Testing
- M2041: Venous and Arterial Thrombosis Risk Testing
- M2057: Diagnosis of Vaginitis
- M2065: Molecular Profiling for Cancers of Unknown Primary Origin
- M2068: Testing For Alpha-1 Antitrypsin Deficiency
- M2069: Genetic Testing of CADASIL Syndrome
- M2070: Genetic Testing for CHARGE Syndrome
- M2071: Genetic Testing and Genetic Expression Profiling in Patients with Uveal Melanoma
- M2072: Genetic Testing For Diagnosis Of Inherited Peripheral Neuropathies
- M2074: Genetic Testing for Muscular Dystrophies
- M2075: Genetic Testing for Epilepsy
- M2077: Genetic Testing for Fanconi Anemia
- M2078: Genetic Testing for Germline Mutations of the RET Proto-Oncogene
- M2079: Genetic Testing for Hereditary Pancreatitis
- M2080: Genetic Testing For Lactase Insufficiency
- M2081: Genetic Testing For Li-Fraumeni Syndrome
- M2082: Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment and or CVD Risk Assessment
- M2083: Genetic Testing for Ophthalmologic Conditions
- M2085: Genetic Testing of Mitochondrial Disorders
- M2087: Genetic Testing For PTEN Hamartoma Tumor Syndrome
- M2088: Genetic Testing for Rett Syndrome
- M2091: Transplant Rejection Testing
- M2097: Identification of Microorganisms using Nucleic Acid Probes
- M2101: Mutation Analysis in Myeloproliferative Neoplasms
- M2108: Molecular Markers in Fine Needle Aspirates of the Thyroid
- M2112: Nerve Fiber Density Testing
- M2114: Pancreatic Cancer Risk Testing Using Pancreatic Cyst Fluid
- M2116: Human Immunodeficiency Virus (HIV)
- M2126: Use Of Common Genetic Variants (Single Nucleotide Polymorphisms) To Predict Risk Of Non-Familial Breast Cancer
- M2131: Genetic Testing for Alpha- and Beta-Thalassemia
- M2134: Genetic Testing for Neurofibromatosis and Related Disorders
- M2137: Genetic Testing for Familial Hypercholesterolemia
- M2139: Molecular Analysis for Gliomas
- M2141: Testing of Homocysteine Metabolism-Related Conditions
- M2144: Testing for Connective Tissue Disorders
- M2145: General Genetic Testing Germline Disorders
- M2146: General Genetic Testing Somatic Disorders
- M2160: Molecular Testing for Pulmonary Disease
- M2166: Gene Expression Profiling and Protein Biomarkers for Prostate Cancer
- M2167: Genetic Testing For Neurodegenerative Disorders
- M2168: Proteogenomic Testing of Individuals with Cancer
- M2170: Red Blood Cell Molecular Testing
- M2171: Esophageal Pathology Testing
- M2172: Onychomycosis Testing
- M2175: Minimal Residual Disease (MRD)
- M2177: Fibromyalgia Testing
- M2178: Microsatellite Instability and Tumor Mutational Burden Testing
- M2179: Prenatal Screening (Genetic)
- M2180: Genetic Markers for Assessing Risk of Cardiovascular Disease
- M2182: Genomic Testing for Hematopoietic Neoplasms
- P2018: Immunohistochemistry
- R2162: Laboratory Procedures Reimbursement Policy
- T2015: Prescription Medication and Illicit Drug Testing in the Outpatient Setting